Meeuwsen, Miranda H.
Wouters, Anne K.
Wachsmann, Tassilo L. A.
Hagedoorn, Renate S.
Kester, Michel G. D.
Remst, Dennis F. G.
van der Steen, Dirk M.
de Ru, Arnoud H.
van Hees, Els P.
Kremer, Martijn
Griffioen, Marieke
van Veelen, Peter A.
Falkenburg, J. H. Frederik
Heemskerk, Mirjam H. M.
Funding for this research was provided by:
KWF Kankerbestrijding (KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831, KWF UL-2014-6831)
Article History
Received: 17 November 2022
Accepted: 9 February 2023
First Online: 27 February 2023
Declarations
:
: Patient and healthy donor materials were collected after written informed consent according to the Declaration of Helsinki. MM patient material from the Leiden University Medical Center Biobank for Hematologic Diseases was used in this study. The study was approved by the Institutional Review Board of the Leiden University Medical Center (approval number 3.4205/010/FB/jr) and the METC-LDD (approval number HEM 008/SH/sh).
: JHFF and MHMH are inventors on a filed patent application (patent number P319797NL) ‘T cell receptors against Jchain and uses thereof.’ The other authors declare no competing interests.